Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
Public ClinicalTrials.gov record NCT00601523. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have previously completed a pramipexole double-blind study in early PD (248.524(NCT00479401) or 248.636(NCT00558025) trial).
Study identification
- NCT ID
- NCT00601523
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 511 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- May 31, 2010
- Completion
- Not listed
- Last update posted
- Jun 8, 2014
Started 2008
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 248.633.01004 Boehringer Ingelheim Investigational Site | Sun City | Arizona | — | — |
| 248.633.01018 Boehringer Ingelheim Investigational Site | Tempe | Arizona | — | — |
| 248.633.01016 Boehringer Ingelheim Investigational Site | La Jolla | California | — | — |
| 248.633.01013 Boehringer Ingelheim Investigational Site | Oxnard | California | — | — |
| 248.633.01008 Boehringer Ingelheim Investigational Site | Danbury | Connecticut | — | — |
| 248.633.01010 Boehringer Ingelheim Investigational Site | Boca Raton | Florida | — | — |
| 248.633.01012 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 248.633.01001 Boehringer Ingelheim Investigational Site | Kansas City | Kansas | — | — |
| 248.633.01005 Boehringer Ingelheim Investigational Site | Commack | New York | — | — |
| 248.633.01009 Boehringer Ingelheim Investigational Site | Burlington | Vermont | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 109 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00601523, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2014 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00601523 live on ClinicalTrials.gov.